Role of human cripto-1 in tumor angiogenesis

被引:67
作者
Bianco, C
Strizzi, L
Ebert, A
Chang, C
Rehman, A
Normanno, N
Guedez, L
Salloum, R
Ginsburg, E
Sun, YP
Khan, N
Hirota, M
Wallace-Jones, B
Wechselberger, C
Vonderhaar, BK
Tosato, G
Stetler-Stevenson, WG
Sanicola, M
Salomon, DS
机构
[1] NCI, Mol & Cellular Endocrinol Sect, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[2] NCI, Extracellular Matrix Sect, Pathol Lab, Expt Transplantat & Immunol Branch,NIH, Bethesda, MD 20892 USA
[3] Dept Gynecol, Berlin, Germany
[4] Univ Michigan, Dept Mol & Cellular Biol, Ann Arbor, MI 48109 USA
[5] ITN, Fdn Pascale, Div Haematol Oncol, Naples, Italy
[6] ITN, Fdn Pascale, Dept Expt Oncol, Naples, Italy
[7] Upper Austrian Res GmbH Zentrum, Linz, Austria
[8] Biogen Idec Inc, Cambridge, MA USA
关键词
D O I
10.1093/jnci/dji011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Human cripto-1 (CR-1) promotes cell transformation and increases migration and invasion of various mouse and human epithelial cell lines. We investigated whether CR-1 also stimulates angiogenesis. Methods: We used human umbilical vein endothelial cells (HUVECs) to measure in vitro migration with fibronectin-coated Boyden chambers, invasion with Matrigel-coated Boyden chambers, proliferation with a tetrazolium salt, and differentiation with an in vitro Matrigel assay. We investigated new blood vessel formation in vivo by use of Matrigel-filled silicone cylinders implanted under the skin of nude mice and by use of a breast cancer xenograft model with CR-1-transfected or control Neo-transfected MCF-7 human breast cancer cells. We also used a blocking anti-CR-1 monoclonal antibody to investigate the role of CR-1 in angiogenesis in vivo and in vitro. All statistical tests were two-sided. Results: CR-1 stimulated HUVEC proliferation, migration, and invasion and induced HUVEC differentiation into vascular-like structures on Matrigel. In vivo recombinant CR-1 protein induced microvessel formation in Matrigel-filled silicone cylinders, and microvessel formation was statistically significantly inhibited with a blocking anti-CR-1 monoclonal antibody (CR-1 and antibody = 127% of microvessel formation compared with that in untreated control cylinders and CR-1 alone = 259%; difference = 132%, 95% confidence interval [CI] = 123% to 140%; P < .001). Tumors formed by CR-1-transfected MCF-7 cells in the cleared mammary fat pad of nude mice had higher microvessel density than tumors formed by control Neo-transfected MCF-7 cells (CR-1-transfected cells = 4.66 vessels per field and Neo-transfected cells = 2.33 vessels per field; difference = 2.33 vessels per field, 95% CI = 1.2 to 2.8; P = .004). Conclusion: CR-1 appears to have an important role in the multistep process of angiogenesis.
引用
收藏
页码:132 / 141
页数:10
相关论文
共 35 条
[11]  
Distler JHW, 2003, Q J NUCL MED, V47, P149
[12]  
Ebert AD, 1999, CANCER RES, V59, P4502
[13]   Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells [J].
Ebert, AD ;
Wechselberger, C ;
Nees, M ;
Clair, T ;
Schaller, G ;
Martinez-Lacaci, I ;
Wallace-Jones, B ;
Bianco, C ;
Weitzel, HK ;
Salomon, DS .
EXPERIMENTAL CELL RESEARCH, 2000, 257 (01) :223-229
[14]   Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase Akt signal transduction pathway -: Requirement for Flk-1/KDR activation [J].
Gerber, HP ;
McMurtrey, A ;
Kowalski, J ;
Yan, MH ;
Keyt, BA ;
Dixit, V ;
Ferrara, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (46) :30336-30343
[15]   Cripto forms a complex with activin and type II activin receptors and can block activin signaling [J].
Gray, PC ;
Harrison, CA ;
Vale, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (09) :5193-5198
[16]   Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay [J].
Guedez, L ;
Rivera, AM ;
Salloum, R ;
Miller, ML ;
Diegmueller, JJ ;
Bungay, PM ;
Stetler-Stevenson, WG .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (05) :1431-1439
[17]   Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto [J].
Harms, PW ;
Chang, CB .
GENES & DEVELOPMENT, 2003, 17 (21) :2624-2629
[18]   SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 [J].
Inman, GJ ;
Nicolás, FJ ;
Callahan, JF ;
Harling, JD ;
Gaster, LM ;
Reith, AD ;
Laping, NJ ;
Hill, CS .
MOLECULAR PHARMACOLOGY, 2002, 62 (01) :65-74
[19]   Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells [J].
Kannan, S ;
DeSantis, M ;
Lohmeyer, M ;
Riese, DJ ;
Smith, GH ;
Hynes, N ;
Seno, M ;
Brandt, R ;
Bianco, C ;
Persico, G ;
Kenney, N ;
Normanno, N ;
MartinezLacaci, I ;
Ciardiello, F ;
Stern, DF ;
Gullick, WJ ;
Salomon, DS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (06) :3330-3335
[20]   Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity [J].
Lang, I ;
Hoffmann, C ;
Olip, H ;
Pabst, MA ;
Hahn, T ;
Dohr, G ;
Desoye, G .
CELL PROLIFERATION, 2001, 34 (03) :143-155